VIVS
VivoSim Labs, Inc.1.9900
+0.0147+0.74%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.19MP/E (TTM)
3.90Basic EPS (TTM)
0.51Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
VivoSim Labs posted Q3 FY2026 revenue of $26K, up 73% y/y from $15K on royalty growth, while product sales ended. Operating loss narrowed to $2.8M from $3.5M y/y, thanks to 36% lower R&D spend amid headcount cuts and no inventory write-downs. YTD revenue held flat at $91K versus $93K, with operating loss shrinking 12% to $8.3M (derived). Cash fell to $4.3M after $8.6M operating burn, offset by $1.8M ATM proceeds; no debt beyond minor insurance financing. Losses track diluted shares. Ongoing H.C. Wainwright litigation poses cash drain risks.
8-K
Annual meeting elects directors
VivoSim Labs held its 2025 Annual Meeting on December 16, electing Douglas Jay Cohen and David Gobel as Class II directors until 2028, with 212,079 and 212,420 votes for, respectively. Stockholders ratified Rosenberg Rich Baker Berman as auditors for fiscal 2026 (97.91% approval) and backed executive pay (89.97%). Annual say-on-pay votes approved. Directors locked in.
10-Q
Q2 FY2026 results
VivoSim Labs held steady with $28K royalty revenue for Q2 FY2026 ended September 30, 2025, matching last year while product revenue vanished post-Mosaic exit; operating loss narrowed to $2.6M from $2.6M (derived), and YTD to $5.6M from $6.0M on 19% R&D cuts via headcount trim. Cash burned $6.3M in operations, leaving $6.7M plus $0.1M restricted at quarter-end, backed by $1.8M ATM proceeds; no debt beyond $0.4M insurance financing at 7.82%. Diluted EPS improved to $(0.98) from $(1.68) on 2.6M vs 1.5M shares, anti-dilutive options excluded. Cash runway tightens.
8-K
CCO appointment to scale services
VivoSim Labs appointed Tony Lialin as Chief Commercial Officer effective August 11, 2025, to lead go-to-market strategy and expand San Diego-based 3D organ model services with AI analytics. Lialin, with 20+ years scaling life science platforms, joins with $360,000 salary, $10,000 sign-on bonus, 40% target bonus, and options for 40,000 shares vesting over four years. He builds revenue engines. Employment is at-will.
10-Q
Q1 FY2026 results
VivoSim Labs narrowed its Q1 FY2026 operating loss to $2.9M from $3.4M y/y, thanks to 29% lower R&D spend and 3% trim in SG&A, while royalty revenue ticked up 48% to $37K sans prior product sales. Cash burn hit $3.9M from operations, leaving $9.1M in cash and $7.6M working capital after $1.8M ATM raise; no debt beyond leases. EPS improved to $(1.14) on 2.5M diluted shares, reconciling cleanly with anti-dilution exclusions. Losses steady. H.C. Wainwright litigation brews over tail fees.
AXIM
Axim Biotechnologies, Inc.
0.02+0.00
BIVI
BioVie Inc.
1.43+0.00
EXOZ
eXoZymes Inc.
12.52-1.78
NOTV
Inotiv, Inc.
0.68-0.02
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
SLP
Simulations Plus, Inc.
18.86-0.57
VANI
Vivani Medical, Inc.
1.41+0.06
VRAX
Virax Biolabs Group Limited
0.40-0.01
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
ZIVO
Zivo Bioscience, Inc.
9.00+0.00